PE20011077A1 - Derivados de cromano que tiene afinidad por receptores de estrogenos - Google Patents

Derivados de cromano que tiene afinidad por receptores de estrogenos

Info

Publication number
PE20011077A1
PE20011077A1 PE2001000199A PE2001000199A PE20011077A1 PE 20011077 A1 PE20011077 A1 PE 20011077A1 PE 2001000199 A PE2001000199 A PE 2001000199A PE 2001000199 A PE2001000199 A PE 2001000199A PE 20011077 A1 PE20011077 A1 PE 20011077A1
Authority
PE
Peru
Prior art keywords
alkyl
affinity
estrogen receptors
chroman derivatives
hal
Prior art date
Application number
PE2001000199A
Other languages
English (en)
Inventor
Gerrit Herman Veeneman
Neeltje Miranda Teerhuis
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20011077A1 publication Critical patent/PE20011077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

SE REFIERE A 4-BENCIL-2-FENILCROMANO DE FORMULA I DONDE R1 ES ALQUILO C1-C4, ALQUENILO C2-C4, ALQUINILO C2-C4; CON ORIENTACION CIS EN RELACION AL FENILO EN LA POSICION 2; R4 ES HAL, CF3, OH, ALQUILOXI C1-C2; R2, R3, R5 SON H, HAL, CF3, ALQUILO C1-C4, ALQUENILO C2-C4, ALQUINILO C2-C4. EL COMPUESTO I TIENE AFINIDAD POR RECEPTORES DE ESTROGENOS UTILES COMO ANTICONCEPTIVOS Y PARA EL TRATAMIENTO DE HIPERTROFIA PROSTATICA BENIGNA, TRASTORNOS CARDIOVASCULARES, MOLESTIAS MENOPAUSICAS, OSTEOPOROSIS, CONTROL DE TUMORES DEPENDIENTES DE ESTROGENOS
PE2001000199A 2000-03-01 2001-02-26 Derivados de cromano que tiene afinidad por receptores de estrogenos PE20011077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200713 2000-03-01

Publications (1)

Publication Number Publication Date
PE20011077A1 true PE20011077A1 (es) 2001-12-12

Family

ID=8171123

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000199A PE20011077A1 (es) 2000-03-01 2001-02-26 Derivados de cromano que tiene afinidad por receptores de estrogenos

Country Status (9)

Country Link
US (3) US7214706B2 (es)
EP (1) EP1282615B1 (es)
JP (1) JP4896335B2 (es)
AR (1) AR027571A1 (es)
AT (1) ATE529419T1 (es)
AU (1) AU2001256164A1 (es)
CO (1) CO5261596A1 (es)
PE (1) PE20011077A1 (es)
WO (1) WO2001064665A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790644A1 (en) * 2001-11-19 2007-05-30 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
ES2286322T3 (es) * 2001-11-19 2007-12-01 Eli Lilly And Company Benzopirianos como agosnistas selectivos de receptores de estrogenos beta.
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
AU2003212856A1 (en) * 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
SI1626974T1 (sl) 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
DE602004025460D1 (de) * 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
DE602005027378D1 (de) 2004-10-18 2011-05-19 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
US9078888B2 (en) 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
EP3490653A1 (en) 2016-07-28 2019-06-05 Cerebral Therapeutics Implantable intraventricular sampling and infusion access device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
DK0937057T3 (da) 1996-10-28 2003-05-05 Novo Nordisk As Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
ATE529419T1 (de) 2011-11-15
JP2003525285A (ja) 2003-08-26
EP1282615A1 (en) 2003-02-12
AR027571A1 (es) 2003-04-02
US20090221695A1 (en) 2009-09-03
EP1282615B1 (en) 2011-10-19
WO2001064665A1 (en) 2001-09-07
AU2001256164A1 (en) 2001-09-12
US7214706B2 (en) 2007-05-08
US7531571B2 (en) 2009-05-12
JP4896335B2 (ja) 2012-03-14
US20060160889A1 (en) 2006-07-20
CO5261596A1 (es) 2003-03-31
US7846966B2 (en) 2010-12-07
US20030069303A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
PE20011077A1 (es) Derivados de cromano que tiene afinidad por receptores de estrogenos
UA71059C2 (uk) Спосіб одержання циталопраму
DE60309836D1 (de) Kristalline zeolithische aluminosilikat-zusammensetzung: uzm-9
PE20020206A1 (es) Metodos y composiciones que comprenden nucleosidos para tratar el virus de la hepatitis c
MY129523A (en) 9. alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
GR1004074B (el) Μεθοδος παρασκευης της σιταλοπραμης.
ATE307182T1 (de) Polyamine mit alkylglycidyletherendgruppen als schaumregulierungsmittel
DK0900234T3 (da) 21-substituerede progesteronderivater anvendt som nye antigestagener
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
TR200101874T1 (tr) Sitalopram hazırlanması için yöntem
CO5040216A1 (es) Agonistas de adenosina a 1, proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5190715A1 (es) 1,2,3,4,5,6-hexahidroazepin [4,5-b] indoles que contienen arilsulfonas en la posicion 9
WO2003051860A3 (en) Substituted 2-phenyl benzofurans as estrogenic agents
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
BR0211899A (pt) Processo para a preparação de um derivado de 14-hidroxinormorfinona, derivados de 14-hidroxinormorfinona e de morfinona, processo para a preparação de um composto, derivado de morfina, e, processo para a produção de noroximorfona
ATE260285T1 (de) Geschützte phenylalkylsilane
BR0014461A (pt) Composto e método para preparar o mesmo
AR031941A1 (es) Proceso para la preparacion de derivados de fenetilamina
BG105847A (en) Calcilytic compounds
PT763024E (pt) Novos processos e intermediarios para a preparacao de derivados de piperazina
BR9900179A (pt) Processo para a preparação de um composto.
CO5080758A1 (es) DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL
BR0003919A (pt) Composto desodorizador de ambiente não tóxico, livre de tensoativo aquoso monofásico e dispositivo desodorizador de ambiente
BR0209714A (pt) Aditivos de alquil hidrazida para lubrificantes
BR0111774A (pt) Material de construção

Legal Events

Date Code Title Description
FD Application declared void or lapsed